Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Candel Therapeutics

- PMLiVE

Candel Therapeutics appoints Mark Sims as Chief Commercial Officer

Sims previously held senior level roles at AstraZeneca, Novartis and Merck

- PMLiVE

FDA grants fast track designation to Candel’s immunotherapy in pancreatic cancer

The disease is the fourth leading cause of cancer-related death in the US, accounting for 3.3% of new cancer cases

- PMLiVE

Candel announces promising results for immunotherapy candidate in pancreatic cancer

Pancreatic cancer accounts for approximately 3.3% of all new cancer cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links